Quiz: Sympathetic Nervous System Pharmacology — 8 Fragen

1. What is the Sympathetic Nervous System primarily responsible for?

A. Regulating involuntary organ functions during stress responses

B. Controlling voluntary muscle movements

C. Processing sensory information from the skin

D. Controlling conscious thought and decision-making

Answer: (A)

Erklärung

The Sympathetic Nervous System is a component of the autonomic nervous system responsible for regulating involuntary organ functions, especially during stress responses, by activating effectors through neural pathways and mediators, as described by Dr. BERERHI (2026).

2. Who is credited with describing the role of neurotransmitters in the sympathetic nervous system in the provided course content?

A. Dr. BERERHI

B. Dr. Smith

C. Dr. Johnson

D. Dr. Lee

Answer: (A)

Erklärung

Dr. BERERHI (2026) is explicitly cited as the author who described the role of neurotransmitters in the sympathetic nervous system, including their chemical mediation at synapses and systemic responses.

3. What is the primary role of adrenergic receptors in the sympathetic nervous system?

A. They mediate specific physiological responses such as vasoconstriction, cardiac stimulation, and bronchodilation.

B. They produce hormones that regulate blood sugar levels.

C. They serve as structural components in nerve cell membranes.

D. They generate nerve impulses that directly cause muscle contraction.

Answer: (A)

Erklärung

Adrenergic receptors are responsible for mediating the physiological effects of catecholamines like adrenaline and noradrenaline, such as vasoconstriction, increased heart rate, and bronchodilation, which are essential functions of the sympathetic nervous system.

4. When was adrenaline first established or used as a sympathomimetic drug?

A. In the 1800s

B. In the 2000s

C. In the early 1900s

D. In the 1950s

Answer: (C)

Erklärung

Adrenaline was first isolated and used in the early 20th century, around the early 1900s, making it the earliest sympathomimetic drug among those listed. Its discovery and medical use marked a significant advancement in emergency medicine and pharmacology.

5. How do sympatholytic drugs differ from sympathomimetic drugs in their mechanism of action?

A. Sympatholytic drugs increase neurotransmitter release, while sympathomimetics inhibit neurotransmitter synthesis.

B. Sympatholytic drugs inhibit or block adrenergic receptors, whereas sympathomimetics activate these receptors.

C. Sympatholytic drugs inhibit enzymes degrading catecholamines, while sympathomimetics stimulate receptor activity.

D. Sympatholytic drugs activate adrenergic receptors directly, while sympathomimetics block them.

Answer: (B)

Erklärung

Sympatholytic drugs differ from sympathomimetics in that they inhibit or block adrenergic receptors, reducing sympathetic activity, whereas sympathomimetics activate these receptors to mimic sympathetic responses.

6. Who is credited with describing the pharmacological effects of adrenergic receptor activation, such as vasoconstriction, cardiac stimulation, and bronchodilation?

A. Paul Ehrlich

B. William Harvey

C. Louis Pasteur

D. Dr. BERERHI

Answer: (D)

Erklärung

Dr. BERERHI (2026) is credited with describing the pharmacological effects of adrenergic receptor activation, including vasoconstriction, cardiac stimulation, bronchodilation, and other systemic responses. The other options are notable scientists but are not associated with this specific description of adrenergic effects.

7. Activation of which adrenergic receptor primarily causes vasoconstriction in blood vessels?

A. Vasoconstriction of blood vessels

B. Vasodilation of blood vessels

C. Increased cardiac contractility

D. Lipolysis in adipose tissue

Answer: (A)

Erklärung

Activation of α1 adrenergic receptors on vascular smooth muscle causes vasoconstriction, leading to increased blood pressure. The other options are effects mediated by different adrenergic receptors: vasodilation is mainly β2, increased cardiac contractility is β1, and lipolysis is β3.

8. In clinical practice, when prescribing sympathomimetic drugs, what is the most important consideration regarding drug interactions with MAO inhibitors or tricyclic antidepressants?

A. Monitor for signs of excessive adrenergic stimulation and avoid concurrent use

B. Increase the dose of sympathomimetics to overcome reduced efficacy

C. Ignore interactions as they are clinically insignificant

D. Prescribe a higher dose of MAO inhibitors to balance effects

Answer: (A)

Erklärung

Combining sympathomimetics with MAO inhibitors or tricyclic antidepressants can significantly enhance adrenergic effects, risking hypertensive crises or arrhythmias. Therefore, clinicians should monitor for signs of excessive stimulation and avoid concurrent use whenever possible.